Adaptive Biotechnologies and Collaborators Present 13 Studies...

Data Validates Clinical Advantage of Tracking Minimal Residual Disease with the clonoSEQ" Test in Patients with ALL, CLL, MM, DLBCL Quantitative Assessment of T Cell Repertoire Diversity by immunoSEQ" Informs Cord Blood and Solid Organ Transplantation Adaptive Biotechnologies and Collaborators Present 13 Studies Demonstrating Clinical Relevance of Immunosequencing at 56th Annual Meeting of the American Society for Hematology Data Validates Clinical Advantage of Tracking Minimal Residual Disease with the clonoSEQ Test in Patients with ALL, CLL, MM, DLBCL /PRNewswire/ -- Adaptive Biotechnologies, the pioneer of Next Generation Sequencing of the adaptive immune system, and its collaborators will present data demonstrating how immunosequencing can inform clinical care in patients with blood cancers at the American Society of Hematology meeting from Immunosequencing is an emerging field where ... (more)

http://ift.tt/1rURHkJ